Form 4: Essa Pharma Director Franklin Berger Reports Acquisition of 50,000 Options
SEC Form 4 Filing
Director Franklin Berger reported acquiring 50,000 options of Essa Pharma Inc. on March 25, 2024.
Summary
- On March 28, 2024, Franklin Berger, a director of Essa Pharma Inc., filed a Form 4 with the SEC.
- The report details a transaction on March 25, 2024, where Berger acquired 50,000 options of Essa Pharma Inc.
- These options have an exercise price of $9.04 and expire on March 25, 2034.
- The options vest on March 25, 2025.
- Following the reported transaction, Berger directly owns 50,000 derivative securities.
Sentiment
Score: 5
Explanation: The document is a standard SEC filing reporting an insider transaction. It doesn't inherently convey positive or negative sentiment.
Industry Context
This filing is a routine disclosure of insider transactions, which are common in the pharmaceutical industry as executives and directors are often compensated with stock options.
Stakeholder Impact
- The acquisition of options by a director could be perceived positively by shareholders as it aligns the director's interests with the company's long-term success.
Key Dates
| Date | Description |
|---|---|
| 03/25/2024 | Date of transaction: Franklin Berger acquired 50,000 options. |
| 03/25/2025 | Options vest. |
| 03/25/2034 | Options expire. |
| 03/28/2024 | Date of Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.